US 11845989
Treatment of ophthalmic conditions with angiopoietin-like 7 (ANGPTL7) inhibitors
granted A61KA61K31/713A61K38/556
Quick answer
US patent 11845989 (Treatment of ophthalmic conditions with angiopoietin-like 7 (ANGPTL7) inhibitors) held by REGENERON PHARMACEUTICALS, INC. expires Mon Dec 14 2043 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- REGENERON PHARMACEUTICALS, INC.
- Grant date
- Tue Dec 19 2023 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Dec 14 2043 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 4
- CPC classes
- A61K, A61K31/713, A61K38/556, A61P, A61P27/02